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Chemical screening profiles on blood specimens 
are designed to yield information that may lead to 
new and additional clinical diagnoses, to revision of 
clinically established diagnoses, to confirmed impres-
sions of the physician and to following the course of 
diseases during a patient's hospitalization. Screening 
profiles on blood are designed to indicate diseases of 
the liver, kidney, heart, striated muscle and other 
organs; they may be helpful in the diagnosis of 
anemia, diabetes mellitus, gout, congestive heart 
failure, osteomalacia and hyperlipidemia, hyperpara-
thyroidism and other diseases. When these screening 
profiles were first introduced, there was widespread 
skepticism among physicians as to their value and 
their yield and some skepticism remains as to the 
usefulness of a broad spectrum of laboratory tests. 
The relative number of new clinical diagnoses 
generated from blood chemistry screening profiles 
has been reported in five studies of three different 
patient populations: hospital patients, hospital clinic 
patients and patients presenting to doctors' offices 
(Table 1). The percentage of new diagnoses ranged 
from 3-16.9% with the percentage tending to in-
crease with the number and selection of tests. New 
clinical diagnoses were obtained in 4% and 8.3% 
of hospital patients, 3 % of hospital clinic patients, 
and 5.5% and 16.9% of patients presenting to doc-
tors' offices. The blood chemistries that were most 
frequently abnormal were glucose, bilirubin, alkaline 
phosphatase, serum glutamic oxalacetic transaminase 
(SGOT), lactic dehydrogenase (LDH), uric acid, 
cholesterol, creatinine, urea nitrogen and hemo-
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globin; the diagnoses that were suggested and sub-
sequently confirmed by the abnormal blood chem-
istries are given in Table 2. Diagnoses other than 
those listed in this table were generated but at a 
lower frequency. 
Occasionally, elevated calcium led to a diag-
nosis of primary hyperparathyroidism and an ele-
vated protein led to a diagnosis of multiple myeloma. 
If these blood screening profiles had uniformly in-
cluded other blood tests, such as iron and iron bind-
ing capacity for anemia, triglycerides for hyper-
lipoproteinemia and protein bound iodine (PBI) or 
thyroxine (T-4) for thyroid disease, then the per-
centage of patients yielding new diagnoses would 
have increased. It must be emphasized that the initial 
chemical screening tests in themselves did not usually 
lead directly to the assigned diagnosis but more 
definitive tests were required. 
Table 2 indicates the laboratory screening 
values that generated new clinical diagnoses and in 
most instances, required a change in treatment. Thus, 
the screening tests contributed to the recognition of 
otherwise unsuspected disease. The abnormal test 
results may be of value in arriving at earlier diag-
noses, earlier treatment and reduction of time for 
subsequent investigation since the results are avail-
able sooner than under previous conditions where 
laboratory tests were ordered individually. If clinical 
features alone were used to guide the physician in 
ordering laboratory tests, abnormal test values would 
be obtained in less than 1.5 % of the patients ( 4) . 
Selection of the most appropriate tests for chemical 
screening is still not complete since different popula-
tions of patients may require different groupings of 
chemical screening tests. 
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TABLE 1 
N EW DIAGNOSES OBTAINED BY CHEMICAL SCREENING PROFILES 
ON BLOOD IN DIFFERENT PATIENT POPULATIONS 
Patient Population 
Hospital Patients 
Hospital Clinic Patients 
Patients Presenting to 
Doctors' Offices 
Percent of Patients Yielding New 
Diagnoses 
4.0 (Belliveau et al., 1970) 
8. 3 (Carmalt et al., 1970) 
3. 0 (Young and Drake, 1966) 
5 . 5 (Percy-Robb et al., 1971) 
16. 9 (Carmalt et al. , 1970) 
TABLE 2 
ABNORMAL BLOOD CHEMISTRIES BY CHEMICAL SCREENING 
PROFILES AND FREQUENTLY FOUND NEW DIAGNOSES 
Abnormal Blood Chemistries Diagnoses 
Glucose Diabetes Mellitus 
Inadequate Control 
Bilirubin Liver Disease 
Congestive Heart · Failure 
Alkaline Phosphatase Liver Disease 
Osteomalacia 
Serum Glutamic Oxalacetic 
Transaminase (SGOT) 















Data are not included on abnormal laboratory 
values that tended to confirm the impressions of the 
physician based on his history and physical examina-
tion of the patient. These profiles also contribute to 
patient care by providing indicated laboratory tests 
rapidly and efficiently (3). These profiles also help 
to detect organ systems that may be functioning 
normally and thus, may not require a doctor's atten-
tion. If these data were available, then the value of 
chemical screening profiles would be even more 
apparent. 
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